TFX vs. GMED, PODD, BAX, RMD, PEN, SOLV, SWAV, GKOS, INSP, and HAE
Should you be buying Teleflex stock or one of its competitors? The main competitors of Teleflex include Globus Medical (GMED), Insulet (PODD), Baxter International (BAX), ResMed (RMD), Penumbra (PEN), Solventum (SOLV), Shockwave Medical (SWAV), Glaukos (GKOS), Inspire Medical Systems (INSP), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.
Teleflex (NYSE:TFX) and Globus Medical (NYSE:GMED) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
Teleflex has a net margin of 9.82% compared to Globus Medical's net margin of 3.51%. Teleflex's return on equity of 14.78% beat Globus Medical's return on equity.
In the previous week, Teleflex had 4 more articles in the media than Globus Medical. MarketBeat recorded 15 mentions for Teleflex and 11 mentions for Globus Medical. Teleflex's average media sentiment score of 0.96 beat Globus Medical's score of 0.85 indicating that Teleflex is being referred to more favorably in the media.
Teleflex has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.
Teleflex currently has a consensus price target of $261.75, suggesting a potential upside of 20.27%. Globus Medical has a consensus price target of $66.50, suggesting a potential upside of 3.26%. Given Teleflex's stronger consensus rating and higher probable upside, equities analysts plainly believe Teleflex is more favorable than Globus Medical.
Teleflex has higher revenue and earnings than Globus Medical. Teleflex is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
95.6% of Teleflex shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 1.4% of Teleflex shares are owned by insiders. Comparatively, 24.3% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Globus Medical received 27 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 67.79% of users gave Globus Medical an outperform vote while only 59.54% of users gave Teleflex an outperform vote.
Summary
Teleflex beats Globus Medical on 12 of the 17 factors compared between the two stocks.
Get Teleflex News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teleflex Competitors List
Related Companies and Tools
